The CHECKMATE 238 trial demonstrated that nivolumab can significantly extend RFS and DMFS even compared with the then-celebrated CTLA-4 inhibitor ipilimumab in stage IIIB/C or IV disease-free melanoma patients [15,16]. The gene discussed is CTLA4; the disease is melanoma.